SCHEMBL4471826

SCHEMBL4471826

Cc1ccccc1S(=O)(=O)Nc1ccc(C=CC(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.57
POLB P06746 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
PKM P14618 1/20 0.56
MEN1 O00255 1/20 0.56
ALDH1A1 P00352 1/20 0.56
KMT2A Q03164 1/20 0.56
HDAC1 Q13547 10/20 0.54
HDAC4 P56524 6/20 0.54
HDAC8 Q9BY41 6/20 0.54
HDAC3 O15379 4/20 0.54
HDAC7 Q8WUI4 4/20 0.54
HDAC2 Q92769 4/20 0.54
HDAC10 Q969S8 4/20 0.54
HDAC11 Q96DB2 4/20 0.54
HDAC6 Q9UBN7 4/20 0.54
HDAC9 Q9UKV0 4/20 0.54
HDAC5 Q9UQL6 4/20 0.54
ESR1 P03372 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471817 1.00 KDM4E (0.57) KDM4EPOLBTDP1L3MBTL1PKM
SCHEMBL25190825 0.83 MAPT (0.54) KDM4EPOLBTDP1PKMMEN1
SCHEMBL2690711 0.81 HDAC1 (0.78) PKMMEN1ALDH1A1KMT2AHDAC1
SCHEMBL2690712 0.81 HDAC1 (0.78) PKMMEN1ALDH1A1KMT2AHDAC1
SCHEMBL11110980 0.81 POLB (0.56) KDM4EPOLBTDP1L3MBTL1MEN1
SCHEMBL633994 0.79 ALDH1A1 (0.68) TDP1L3MBTL1PKMMEN1ALDH1A1
SCHEMBL1403082 0.79 HDAC1 (0.78) PKMMEN1ALDH1A1KMT2AHDAC1
SCHEMBL11131607 0.79 ALDH1A1 (0.52) TDP1L3MBTL1PKMMEN1ALDH1A1
SCHEMBL1403084 0.79 HDAC1 (0.78) PKMMEN1ALDH1A1KMT2AHDAC1
SCHEMBL3718775 0.79 TSHR (0.65) POLBTDP1MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2093292-A2 Inhibition of specific histone deacetylase isoforms Methylgene, Inc. (CA) 2009-08-26 EP disclosed
US-20040266718-A1 Inhibition of specific histone deacetylase isoforms LI ZUOMEI (CA) 2004-12-30 US disclosed
EP-1438404-A2 INHIBITION OF SPECIFIC HISTONE DEACETYLASE ISOFORMS Methylgene, Inc. (CA) 2004-07-21 EP disclosed
WO-2003006652-A2 INHIBITION OF SPECIFIC HISTONE DEACETYLASE ISOFORMS METHYLGENE, INC. (CA) 2003-01-23 WO disclosed
US-20020061860-A1 Antisense oligonucleotide inhibition of specific histone deacetylase isoforms METHYLGENE, INC. (CA) 2002-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061860-A1 Antisense oligonucleotide inhibition of specific histone deacetylase isoforms HDAC5, HDAC1, HDAC8 KDM4E 737/4885POLB 166/4885TDP1 451/4885
US-20040266718-A1 Inhibition of specific histone deacetylase isoforms HDAC1, HDAC5, HDAC3 KDM4E 223/4885POLB 517/4885TDP1 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.